WS #11745

18:22→18:52 UTC

From 499 msgs · 7 key-dev

AstraZeneca's Wainua (eplontersen) fails Phase 3 trial in transthyretin-mediated amyloid cardiomyopathy, stock falls 6.2%.

AstraZeneca Drug Trial Failure

AstraZeneca's Wainua (eplontersen) fails Phase 3 trial in transthyretin-mediated amyloid cardiomyopathy, stock falls 6.2%.